Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

2005 ◽  
Vol 3 (3) ◽  
pp. 103-110 ◽  
Author(s):  
Paul D. Miller
Keyword(s):  
Bone Density ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Markers Of Bone Turnover ◽  
Fracture Risk Reduction ◽  
Predict Fracture Risk

scholarly journals Biomarkers of bone health and osteoporosis risk

2008 ◽  
Vol 67 (2) ◽  
pp. 157-162 ◽  
Author(s):  
Richard Eastell ◽  
Rosemary A. Hannon
Keyword(s):  
Bone Turnover ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Hormone Replacement ◽  
Osteoporosis Treatment ◽  
Bone Alkaline Phosphatase ◽  
Type I ◽  
Mineral Density ◽  
Markers Of Bone Turnover ◽  
Fracture Risk Reduction

The assay features of biochemical markers of bone turnover have markedly improved in the past few years. The most sensitive and specific markers of bone formation include serum bone alkaline phosphatase, total osteocalcin (including the intact molecule and the large N-mid fragment) and the procollagen type I N-terminal propeptide assay. Among the various markers of bone resorption, measurements of the urinary excretion of N- and C-terminal cross-linked telopeptides) and of serum C-terminal cross-linked telopeptides are the most sensitive and specific. Markers of bone turnover can be used to predict the rate of bone loss in post-menopausal women and can also be used to assess the risk of fractures. In osteoporosis-treatment studies (with alendronate, risedronate, raloxifene) markers of bone turnover appear even more strongly associated with fracture risk reduction than bone mineral density (BMD). These observations support the use of markers of bone turnover as surrogates for fracture risk reduction, perhaps even more so than BMD. Bone markers can also be used to monitor the efficacy of antiresorptive therapy such as hormone-replacement therapy, raloxifene and bisphosphonates in individual patients. Furthermore, they have also proved to be helpful in monitoring the response to nutritional interventions and have the advantage over BMD in that they provide information about mechanism of effect and changes are often observed much more rapidly.

scholarly journals Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression

2018 ◽  
Vol 33 (4) ◽  
pp. 634-642 ◽  
Author(s):  
Douglas C Bauer ◽  
Dennis M Black ◽  
Mary L Bouxsein ◽  
Li-Yung Lui ◽  
Jane A Cauley ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Risk Reduction ◽  
Fracture Risk Reduction ◽  
Meta Regression
Sign in / Sign up

Export Citation Format

Share Document